US Market Report for Patent Foramen Ovale Devices 2018 Market Report; Launched via MarketResearchReports.com

Some studies have suggested that PFO closure can reduce the incidence of migraine headaches. While surgery would be considered too risky a treatment for the vast majority of migraine sufferers, these patients represent a large potential market for a less invasive percutaneous procedure.

As a result, a number of clinical trials including the PREMIUM, PRIMA, CLOSURE I, ESCAPE, MIST I and MIST II clinical trials were created to investigate the use of PFO devices in treating patients with severe migraines. There are additional studies that have focused on migraine patients that have experienced stroke in the past and therefore may not be representative of otherwise healthy migraine patients. It is probable that PFOs contribute to certain types of migraines and PFO closure would be a suitable treatment for only a percentage of PFO patients.

A patent foramen ovale (PFO) is a defect in the septum between the two atrial chambers of the heart. Specifically, the defect is an incomplete closure of the atrial septum that results in the creation of a flap or a valve-like opening in the atrial septal wall. A PFO is distinct from a secundum atrial septal defect (ASD). A PFO is present in everyone before birth but seals shut in most people. In adults, PFO occurs when the atrial septum, which is responsible for recycling blood during womb development, does not properly occlude after birth.

The condition is very common, affecting over 20% of the population. Individuals with PFO are more likely to suffer a stroke and there is evidence that migraines can be a symptom of the condition. Those who have a PFO as well as migraines often experience sensations during their migraine that include shimmering spots, blurred vision and blind spots. There are many cases where PFO patients do not need to undergo surgery and drug treatment and continual monitoring are the only measures that are necessary. However, open surgical and interventional procedures are common in patients who run the risk of having a sudden cardiac arrest.

Spanning over 379 pages “US Market Report for Patent Foramen Ovale Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Patent Foramen Ovale Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/Upv

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Off-Pump Coronary Artery Bypass Devices 2018 Market Report; Launched via MarketResearchReports.com

Off-pump coronary artery bypass (OPCAB), or simply beating-heart coronary artery bypass grafting, utilizes a medial sternotomy to access the heart, similarly to on-pump coronary artery bypass (ONCAB) procedures. The important difference is that the cardiopulmonary bypass pump is not employed. Clinical studies show that OPCAB offers several benefits compared to ONCAB procedures, including reductions in bleeding, decreases in short-term neurocognitive dysfunction, kidney dysfunction and length of hospital stay.

Despite these advantages, the inherent technical challenges of performing OPCAB have impeded its widespread adoption. These off-pump procedures require special techniques and instrumentation in order to perform efficient and reliable anastomosis on the beating heart. The increasing penetration of anastomosis assist devices (AAD) has helped to create precise and reliable anastomoses and slow the decline in OPCAB procedure volume.

It should be noted that all minimally invasive coronary artery bypass graft (CABG) procedures, including minimally invasive direct coronary artery bypass (MIDCAB) and totally endoscopic coronary artery bypass (TECAB), are performed off-pump. These procedures differ from traditional OPCAB techniques in that they do not require a highly invasive medial sternotomy.

OPCAB procedures are much harder to perform because the beating heart adds difficulty in performing a bypass on the posterior and lateral walls of the heart. Surgeons have found many ways to stabilize the heart to bypass the necessary arteries. Most commonly, stabilizer and positioner devices are used in surgeries to aid physicians in stabilizing and positioning the heart and arteries.

Spanning over 393 pages “US Market Report for Off-Pump Coronary Artery Bypass Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Off-Pump Coronary Artery Bypass Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/Up9

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Mechanical Heart Valves 2018 Market Report; Launched via MarketResearchReports.com

The first generation of device designs for mechanical heart valves included a caged-ball construct. These devices functioned similar in fashion to a ballpoint pen, serving as a one-way flow point for blood between the chambers of the heart. However, this design was not ideal in that the heart had to work harder to maintain flow through the valve. Subsequent generations of device design focused on an open-and-close valve, which allowed for central blood flow. Mechanical heart valves may be combined with a conduit for use in cases requiring the reconstruction of both the aortic heart valve and the aorta.

Mechanical heart valves are prosthetic devices designed to replicate the function of the natural valves of the human heart. Mechanical valves are designed to outlast the patient and some have been stress-tested to last several hundred years. Although mechanical valves are long-lasting and generally only require one surgery for installation, they contribute to an increased risk of blood clot formation. As a result, mechanical valve recipients often take anti-coagulant (blood thinning) drugs such as warfarin for the rest of their lives, which makes the patient more prone to bleeding. Given their durability, mechanical valves are primarily indicated for younger patients and for mitral valve replacement due to its high-pressure gradient.

The primary advantage of mechanical over tissue valves is that once a mechanical valve is implanted, they never wear down and rarely need to be replaced. Mechanical valves are made from either pyrolytic carbon or titanium that has been coated with pyrolytic carbon. Pyrolytic carbon is similar to graphite and is used for many biomedical applications. They also can have parts made from Teflon, polyester or polyethylene terephthalate.

Spanning over 386 pages “US Market Report for Mechanical Heart Valves 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Mechanical Heart Valve Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/Upj

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Intra-Aortic Balloon Pumps 2018 Market Report; Launched via MarketResearchReports.com

An intra-aortic balloon pump system is used for the treatment of high-risk cardiac conditions resulting from ischemic heart disease and heart failure. Patients experiencing acute coronary syndromes such as acute myocardial infarction (AMI), cardiogenic shock and unstable angina may require IABP therapy to support and stabilize their cardiac status.

The therapy may also be used for high-risk patients who require revascularization procedures, such as percutaneous coronary interventions (PCI) or coronary artery bypass grafting (CABG) procedures, including both on-pump and off-pump CABG procedures. IABP products and therapy may be used before or during CABG or PCI interventions for hemodynamic support.

The IABP market comprises capital equipment pump console units and disposable intra-aortic balloon catheters that serve as the pumping device within the patient’s aorta. Datascope, now acquired by Maquet, introduced the first balloon catheter capable of percutaneous insertion. This innovation eliminated the restricted use of IABPs to surgical insertion during CABG procedures and allowed for the expansion of IABPs into the realm of interventional cardiology.

Counterpulsation therapy is used during surgery to provide temporary assistance to the heart. Counterpulsation refers to the inflation and deflation of an intra-aortic balloon synchronized with the heartbeat. The therapy increases the heart’s output and the supply of oxygen-rich blood to the heart’s coronary arteries while reducing the heart muscle’s workload and its oxygen demand. Counterpulsation is performed using intra-aortic balloon pump (IABP) devices.

Spanning over 392 pages “US Market Report for Intra-Aortic Balloon Pumps 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Research Methodology, Disease Overview, Product Portfolio, Intra-Aortic Balloon Pump Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UG4

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Extracorporeal Membrane Oxygenation Machines 2018 Market Report; Launched via MarketResearchReports.com

Extracorporeal membrane oxygenation (ECMO) is used as a support device for use in heart failure. ECMO is a miniaturized and simplified form of heart-lung machines. ECMO involves withdrawing venous blood with an active pump and returning oxygenated blood into a major central artery. ECMO is primarily used for patients who need cardiac and lung support. ECMO is divided into three types: veno-arterial (VA), veno-venous (VV) and arteriovenous (AV). VA is used for support during cardiac failure.

The blood is drained from a large central vein, into an oxygenator and re-enters the arterial system at the aorta. VA is generally done as a bridge to left ventricular assist device replacement. VV is the most common mode of ECMO done and is generally utilized for support during respiratory failure. VV is not used for cardiac failure and is a bridge to lung transplant.

The ECMO market includes disposable products and capital equipment. ECMO products have been in the market for a long time but have only recently started gaining traction. ECMO has experienced a reinvigoration due to positive reports and the stagnation of heart-lung machines in the market. The market is expected to grow as more surgeons view the technique as a better alternative to heart-lung machines.

Spanning over 375 pages “US Market Report for Extracorporeal Membrane Oxygenation Machines 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Extracorporeal Membrane Oxygenation Machine Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UGZ

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Endoscopic Vessel Harvesting Devices 2018 Market Report; Launched via MarketResearchReports.com

In an EVH procedure, the EVH device is inserted into the patient via an incision approximately one inch long either in the patient’s leg, arm or chest, depending on the vessel being procured. When the vessel is being removed from the patient’s leg or arm, the non-dominant limb is generally used for decreasing patient discomfort after the procedure. Using endoscopic techniques, any tissue that is connected to the vessel is cut away and the vessel is removed through a secondary incision.

As it lessens patient discomfort and recovery times, EVH procedures have become the preferred method of obtaining vessels for CABG procedures. However, some vessels are still obtained using open harvesting methods at the discretion of the physician.

Coronary artery bypass graft (CABG) procedures involve bypassing a weakened or damaged artery with another vessel to bypass the blocked and diseased portion of the coronary artery and maintain blood flow. The vessels most often used are the saphenous vein in the leg, the radial artery in the arm or the mammary artery from the chest wall.

Vessel harvesting may be performed with an open incision or endoscopically. Endoscopy allows for a small, minimally invasive incision to be made rather than the much larger incision required for open harvesting. Endoscopic vessel harvesting (EVH) devices have become the standard of care for vessel harvesting during CABG procedures performed in the United States.

The vessels obtained using EVH devices provide excellent conduit quality and hemostasis results. Furthermore, EVH procedures reduce patient discomfort and scarring as well as recovery time for the patient. This acts to improve patient outcomes and increase overall satisfaction.

Spanning over 379 pages “US Market Report for Endoscopic Vessel Harvesting Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Endoscopic Vessel Harvesting Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UGJ

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Atrial and Ventricular Septal Defect Devices 2018 Market Report; Launched via MarketResearchReports.com

VSDs are defects in the ventricular septum, the wall dividing the left and right ventricles of the heart. VSDs are similar to ASDs but tend to cause fewer complications because VSDs are small and most people with the defect barely feel the symptoms. However, approximately 10% of individuals with VSD will develop Eisenmenger’s Syndrome, which is a condition that can curtail life expectancy by several years.

This condition can also be found in ASD patients. VSDs are found in approximately 3 to 3.5 of every 1,000 births but the vast majority of VSDs are likely to close spontaneously during childhood. Only in a small percentage of cases, they will have to be treated surgically. ASDs and VSDs can be treated percutaneously by inserting a device through the defect, which expands and forms a seal around the defect. Many of these devices allow heart tissue to grow over the device with time.

Atrial septal defect (ASD) and ventricular septal defect (VSD) are both conditions that involve incorrect blood flow within the heart. ASD is an opening in the muscular tissue that separates the sides of the heart’s two upper chambers. Due to blood reflux, the heart is made to work more strenuously and below its optimal level. The condition is more common in females than males and tends to get worse with time.

If left untreated, ASD can cause hypertension, heart arrhythmia and even a stroke. As with patent foramen ovale (PFO), ASD can be treated with open-heart surgery, but the operation is highly invasive. ASDs are found in approximately 1 in 1,500 live births and can lead to death if not treated in some cases.

Spanning over 384 pages “US Market Report for Atrial and Ventricular Septal Defect Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Atrial And Ventricular Septal Defect Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UGk

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Annuloplasty Repair Devices 2018 Market Report; Launched via MarketResearchReports.com

Heart valves can be repaired through annuloplasty or valvuloplasty. Annuloplasty involves resizing heart valves and a valvuloplasty procedure involves repairing heart valve leaflets, which have calcium deposits or extra tissue on the leaflets. Although all valves may undergo repair procedures, mitral valve repair is by far the most common procedure, followed by tricuspid valve repair. Due to the extremely low numbers of aortic and pulmonary valve procedures, for the purposes of this report, their numbers are considered negligible.

The mitral and tricuspid valves are atrioventricular valves that prevent backflow from the ventricles into the atria during systole. Both valves are anchored to the wall of the ventricle by chordae tendineae, which prevent the valve from inverting. The chordae tendineae are attached to papillary muscles that create tension to hold the valve.

In the past, the mitral valve has been preferred for repair because of the large margin of safety that the valve allows during the repair procedure. However, an article published in the New England Journal of Medicine in November 2013 demonstrated that mitral valve replacement provides a more durable correction of mitral regurgitation than mitral repair. This has increased the popularity of mitral valve replacement for the treatment of mitral valve defects.

Annuloplasty is used for restoring an optimal orifice area and shape, providing support and preventing further annular dilatation. Through disease or age, the tissue that supports the heart valve’s opening, the annulus, can weaken and lose its shape. To repair this condition, a device called an annuloplasty ring or band is sewn around the base of the heart valve to reshape it and give it support.

An annuloplasty band or ring is made of durable plastic, metal or fabric and may be flexible or rigid. These rings and bands are designed to hold the natural shape, motion and flexibility of the annulus. An annuloplasty repair procedure usually involves open heart surgery requiring a median sternotomy, but may also be performed minimally invasively via keyhole surgical techniques or percutaneously.

Spanning over 386 pages “US Market Report for Annuloplasty Repair Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Research Methodology, Disease Overview, Product Portfolio, Annuloplasty Repair Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UG5

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Procedure Numbers for Cardiac Surgery and Heart Valve Devices 2018 Market Report; Launched via MarketResearchReports.com

Recently, minimally invasive cardiac surgery has started to gain popularity among surgeons and patients. Minimally invasive procedures allow for reduced hospitalization and less scarring. The growth of the minimally invasive procedures comes from the cannibalization of the open-heart surgery procedures.

Currently, many types of minimally invasive procedures do not have FDA approval. As more products get FDA approved, the minimally invasive procedures are expected to grow at a much higher rate and cause the open-heart procedures to decline.

Cardiac surgery and heart valve procedures accounts for a large array of procedures. Generally, cardiac surgery is done through open heart surgery where a surgeon opens the chest and heart. For heart valves, the surgeon could replace or repair the damaged heart valve.

Another common cardiac surgery procedure would be coronary artery bypass grafting where a harvested vein is grafted onto the heart to bypass blocked arteries. This procedure can be done on-pump, where a cardioplegic solution is sued to stop the heart and the patient is put on a heart-lung machine, or off-pump, also known as beating heart surgery.

Spanning over 408 pages “US Procedure Numbers for Cardiac Surgery and Heart Valve Devices 2018 - MedPro” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Research Methodology, Disease Overview, Procedure Numbers, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UpH

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Product Portfolio for Cardiac Surgery and Heart Valve Devices 2018 Market Report; Launched via MarketResearchReports.com

Accurate product and industry research is a time consuming and costly affair, but a necessary part of any successful market player. Our MedFolio™ line of products can ease research burdens by compiling the latest product information across an entire market segment. We have aggregated hundreds of products by category and company, as well as comprehensive lists of press releases, regulatory announcements and future product developments. MedFolio is ideal for companies with small or limited research teams as well as those who need to supplement their research departments with new data.

A MedFolio includes the following products (*Not all products are available in every MedFolio, for more information, consult the MedFolio product page of a specific report):

• Executive Summary
• Product Introductions
• Product Portfolio (Current Products on Market)
• Product Pipelines (Future Products)
• Clinical Trials

Accurate product and industry research is a time consuming and costly affair, but a necessary part of any successful market player. Our MedFolio™ line of products can ease research burdens by compiling the latest product information across an entire market segment. We have aggregated hundreds of products by category and company, as well as comprehensive lists of press releases, regulatory announcements and future product developments. MedFolio is ideal for companies with small or limited research teams as well as those who need to supplement their research departments with new data.

A MedFolio includes the following products (*Not all products are available in every MedFolio, for more information, consult the MedFolio product page of a specific report):

• Executive Summary
• Product Introductions
• Product Portfolio (Current Products on Market)
• Product Pipelines (Future Products)
• Clinical Trials

Spanning over 370 pages “US Product Portfolio for Cardiac Surgery and Heart Valve Devices 2018 - MedFolio” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UpV

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for On-Pump Coronary Artery Bypass Devices 2018 Market Report; Launched via MarketResearchReports.com

CPB is also used in heart valve replacement and repair procedures, repair of septal and congenital heart defects and transplants. However, for the purposes of this report, this chapter analyzes the use of CPB specifically in ONCAB procedures. During an ONCAB procedure, the patient’s heart is stopped temporarily while surgeons use a continuous thread and hand sew vessels together to bypass the blockages. During this procedure, a mechanical cardiopulmonary bypass machine keeps the blood circulating through the body.

The blood is rerouted through the healthy vessel and blood flow is restored to the heart muscle. Redirecting the blood flow to a pump enables the surgeon to clamp the aorta and stop the heart, resulting in a motionless and bloodless field. This allows the surgeon to precisely perform manual suturing to obtain accurate connections (anastomoses) between the graft vessel and the aorta, as well as effectively bypass the narrowed or obstructed coronary artery. The absence of blood flow and a motionless heart are important factors in ensuring precision and providing consistent, reproducible positive clinical outcomes.

There are some downsides to the use of CPB pumps. Use of the CPB for circulation exposes the patient’s blood to foreign surfaces, which has been shown to increase the incidence of bleeding and short-term neurocognitive defects. This is known as post-perfusion syndrome or “pump head.” Symptoms of post-perfusion syndrome are subtle and include defects associated with attention, concentration, short-term memory, fine motor function and speed of mental and motor responses.

Additionally, stopping of the heart may damage the heart muscle. In certain studies, clamping of the aorta has been shown in certain studies to cause the release of particles into the blood stream that may produce blockages in other parts of the body, such as the brain, which may lead to neurological damage, including strokes. Despite these potential complications, the majority of CABG procedures are still performed on-pump. Furthermore, the percentage of total CABG procedures performed on-pump has been increasing year-over-year since 2004.

The majority of coronary artery bypass graft (CABG) procedures are performed with the heart stopped. This type of procedure is termed on-pump coronary artery bypass (ONCAB) because the procedure requires the usage of a cardiopulmonary bypass (CPB). CPB is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body. The CPB pump itself is often referred to as a heart-lung machine.

In addition to the heart-lung machine, a complete extracorporeal bypass system is composed of various single-use products, called disposables for the purposes of this report. As disposables come into direct contact with the patient’s blood, they cannot be reused for safety reasons and must be disposed of and replaced following each procedure.

Spanning over 381 pages “US Market Report for On-Pump Coronary Artery Bypass Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, On-Pump Coronary Artery Bypass Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UG3

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Temporary Artificial Heart Replacement Devices 2018 Market Report; Launched via MarketResearchReports.com

SynCardia’s CardioWest™ was the world’s first FDA-approved total artificial heart. It received FDA approval in October 2004 following a ten-year pivotal clinical study. The CardioWest™ was originally designed as a permanent replacement heart, but was approved as a bridge-to-transplant device for patients dying due to irreversible end-stage biventricular failure in which both the left and right ventricles of their hearts are failing. SynCardia’s CardioWest™ is now marketed as the SynCardia Total Artificial Heart™. As of 2017, SynCardia’s Total Artificial Heart™ has been implanted in over 1,700 cases worldwide, with over 500 implants in the United States. It is estimated to have accounted for more than 600 patient years of extended life on the device.

Artificial heart devices can be temporary or permanent mechanical devices that are designed to replace the function of a biological heart. The term “artificial heart” should not be used for describing ventricular assist devices (VADs). VADs are pumps that assist the heart but are not designed to replace it. Instead, they are used in collaboration with a patient’s heart. An artificial heart is also distinct from a cardiopulmonary bypass machine (CPB), which is an external device used for providing the functions of both the heart and lungs. CPBs are only used for a few hours at a time, most commonly during heart surgery. Artificial hearts were originally intended to be a permanent replacement for the biological human heart.

Spanning over 381 pages “US Market Report for Temporary Artificial Heart Replacement Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Temporary Artificial Heart Replacement Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UpF

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Ventricular Assist Devices 2018 Market Report; Launched via MarketResearchReports.com

The American Heart Association (AHA) estimates that 5.1 million people suffer from HF in the U.S. and approximately 550,000 new cases are diagnosed each year. Pharmacologic therapies remain the most widely used approach for treatment of HF but heart transplantation remains the only curative option for late stages of the disease. Other procedures to treat HF include angioplasty, biventricular pacing, valve replacement, bypass and left ventricular reduction surgery.

VADs are designed to assist either the left (LVAD), the right (RVAD) ventricle, or both at the same time (BiVAD). The choice of device depends on the underlying heart disease and the pulmonary arterial resistance that determines the load on the right ventricle. LVADs are by far the most commonly performed procedures but when pulmonary resistance is high, right ventricular assist becomes necessary. Biventricular assist devices supply circulatory support to both the right and left ventricle of the heart, by pumping blood to both the systemic and pulmonary systems.

Being an assist device, a BiVAD functions in conjunction with the native heart, unlike a total artificial heart with which the native heart is removed. By retaining the native ventricles of the heart, a BiVAD allows for the possibility of myocardial recovery, which would eliminate the need for cardiac transplantation. For the purpose of this report, VADs are segmented into three categories: percutaneous ventricular assist devices (pVADs), implantable ventricular assist devices and external ventricular assist devices. Implantable VADs are used for bridge-to-recovery (BTR), bridge-to-transplant (BTT) and destination therapy (DT). These labels are described briefly below.

Ventricular assist devices (VADs) are used for aiding a failing heart by supplementing the pumping function of the heart. VADs are often used in patients with advanced heart failure (HF). HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pump power of the heart, which causes the heart to become too weak to pump blood at a level sufficient to meet the body’s demands. The condition may be caused by arterial and valve diseases or cardiomyopathy, which is disease of the heart muscle itself. Other conditions such as high blood pressure or diabetes may also lead to HF.

Spanning over 381 pages “US Market Report for Ventricular Assist Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Research Methodology, Disease Overview, Product Portfolio, Ventricular Assist Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/Upy

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Left Atrial Appendage Closure Devices 2018 Market Report; Launched via MarketResearchReports.com

Atrial fibrillation (AF) is an abnormal heart rhythm. Patients with AF experience episodes of rapid and irregular beating. As a result of irregular beating, the atrium in AF patients does not completely contract, impeding the flow of blood from the atria into the ventricles. Blood that is not expelled from the left atria collects in the sac-shaped LAA.

Once in the LAA, movement of the blood slows. As blood slows, it tends to clot. Strokes can be caused when blood clots are pumped out of the heart. As a result of increased blood clot formation, AF patients are five to seven times more likely to suffer a stroke than those without AF.

Some patients with AF take a blood thinner, such as warfarin (Coumadin), to reduce the risk of stroke. However, many AF patients dislike taking warfarin due to the increased risk of bleeding, the need to limit vitamin K intake and the increased need for blood draws to measure their international normalized ratio (INR).

LAA closure devices were developed as an alternative method of reducing the risk of stroke in AF patients. LAA closure devices are used to seal off the LAA, preventing clot formation in the LAA and eliminating the need for the patient to take blood-thinning medication.

The left atrial appendage (LAA) is a small pouch in the wall of the left atrium. It is unknown what function the LAA performs.

In patients with normal heart rhythm, the heart contracts with each heartbeat. As the heart contracts, blood is pushed from the left atrial appendage into the left atrium and from the left atrium into the left ventricle.

Spanning over 394 pages “US Market Report for Left Atrial Appendage Closure Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Left Atrial Appendage Closure Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UGU

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Anastomosis Assist Devices 2018 Market Report; Launched via MarketResearchReports.com

The traditional and most common method of performing anastomosis typically involves tedious and time-consuming hand-sewn placement of individual stitches with a continuous suture to connect the bypass graft proximally to the aorta and distally to the coronary vessels. Anastomosis is viewed by surgeons as the most critical step in performing CABG procedures, and using traditional methods, the process can take 10 to 25 minutes to perform the necessary suture for each point of anastomosis.

Most surgeons prefer to use a continuous suture because placement of sutures individually is considered to be more challenging and time-consuming. Whether the procedure is on-pump or off-pump, hand-sewn proximal anastomosis generally requires clamping of the aorta, which carries the risk of neurological damage and other serious adverse effects. Although methods to allow hand-sewn proximal anastomosis without clamping have been developed, the time-consuming nature of manually applied sutures and the limitations associated with their use have fueled the need for fast, efficient and reliable automated systems to hasten and facilitate anastomoses done during CABG procedures.

Thus, AADs have been developed for this purpose and replace the need for surgeons to manually hand suture two blood vessels to perform the anastomosis. The growing popularity of AADs has helped to significantly reduce surgical procedure times. In addition, AADs have significantly reduced the inherent difficulty in performing anastomosis in beating-heart procedures.

Anastomosis assist devices (AADs) are used for joining two blood vessels, usually to restore continuity after resection, or to bypass an unresectable disease process. Coronary artery bypass graft (CABG) involves the construction of an alternative path to bypass a narrowed or occluded diseased coronary artery and restore blood flow from the aorta to an area beyond the occlusion. This is accomplished by using harvested veins or arteries as bypass grafts. This harvested vessel is usually the saphenous vein in the leg, the radial artery in the arm or the mammary artery from the chest wall.

One end of the harvested vessel is then generally attached to the aorta (proximal anastomosis) and the opposite end is attached to the target coronary vessel on the heart (distal anastomosis). If the mammary artery is used as the bypass graft, it is dissected from the chest wall, leaving the blood inflow end in place, while the opposite dissected end is attached to the target vessel. This provides uninterrupted blood flow and eliminates the need for proximal anastomosis to the aorta. Regardless of the type of vessel used, once in place, these grafts provide sufficient blood flow to bypass the narrowed or occluded portion of the coronary artery.

Spanning over 387 pages “US Market Report for Anastomosis Assist Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Research Methodology, Disease Overview, Product Portfolio, Anastomosis Assist Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UpC

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market for Cardiac Surgery and Heart Valve Devices 2018 Market Report; Launched via MarketResearchReports.com

Cardiac surgery involves the heart and the great vessels connected to the heart. It is often performed to treat ischemic heart disease, congenital heart disease, valvular heart disease as well as heart transplantation. The first cardiac surgeries were performed in the 19th century on the pericardium, the sac that surrounds the heart.

The first surgery on the heart itself was performed in 1895 in Oslo, Norway. Surgeon Axel Cappelen ligated the bleeding coronary artery of a 24-year-old patient who had been stabbed under his left arm. The patient survived for over two days but later passed away due to infection from the procedure. Approximately one year afterwards, a successful operation was performed in Germany on another patient with a stabbing injury.

There are many risks associated with performing cardiac surgery. Patients often suffer from neurological damage and strokes after procedures. Neurological damage is more common when an ONCAB procedure is performed; many patients suffer from post-perfusion syndrome, which is a combination of neurological conditions that can affect patients after surgery. These symptoms can be temporary or permanent.

The U.S. market for cardiac surgery and heart valve devices includes tissue heart valves, mechanical heart valves, annuloplasty repair devices, transcatheter mitral valve repair (TMVR) devices, transcatheter heart valve replacement (THVR) devices, on-pump coronary artery bypass (ONCAB) devices, off-pump coronary artery bypass (OPCAB) devices, endoscopic vessel harvesting (EVH) devices, anastomosis assist devices (AADs), transmyocardial revascularization (TMR) devices, ventricular assist devices (VADs), intra-aortic balloon pumps, temporary artificial heart replacement devices, extracorporeal membrane oxygenation (ECMO), remote hemodynamic monitoring, patent foramen ovale (PFO), atrial septal defect (ASD) devices, ventricular septal defect (VSD) devices and left atrial appendage (LAA) devices.

Several new and innovative devices within this market are expected to emerge over the forecast period, particularly in the heart valve and cardiac assist segments, and as a result, growth in the overall market is expected to accelerate.

Spanning over 366 pages “US Market for Cardiac Surgery and Heart Valve Devices 2018 - MedView” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UGT

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

US Market Report for Transcatheter Mitral Valve Repair Devices 2018 Market Report; Launched via MarketResearchReports.com

Transcatheter heart valve repair is often referred to as percutaneous heart valve repair (PHVR). The naming conventions are also changed to account for the specific heart valve that the device is indicated for. Devices currently approved and undergoing trials are intended for use on the mitral valve and are thus labeled as transcatheter mitral valve replacement (TMVR) devices.

Abbott Laboratories’ MitraClip™ is the only TMVR device approved for use by the FDA. The MitraClip™ procedure is based on the edge-to-edge surgical method of valve repair. In the MitraClip™ procedure, the steerable guide catheter is inserted into the femoral vein at the groin and provides a conduit to access the mitral valve. The clip delivery system delivers and deploys the MitraClip™, which must be carefully timed by the physician but can be adjusted if the position is not desirable. This procedure is performed while the heart is still beating, without cardiopulmonary bypass or the need for a thoracotomy or sternotomy.

The human heart contains four valves: the mitral valve, tricuspid valve, aortic valve and pulmonary valve. The mitral valve is most prone to regurgitation, which is a condition where blood is funneled back into the left atrium of the heart. Mitral regurgitation (MR) can either be caused by a congenital defect or myxomatous degeneration of the valve. Individuals with MR can suffer from atrial fibrillation, heart muscle dysfunction and even sudden death caused by cardiac arrest. In the U.S., there are just over 4 million people that may have MR, with only a minority actually diagnosed. The standard of care for MR is open surgery and/or the use of annuloplasty rings.

Spanning over 378 pages “US Market Report for Transcatheter Mitral Valve Repair Devices 2018 - MedCore” report covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Transcatheter Mitral Valve Repair Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.

Please visit this link for more details: http://mrr.cm/UGi

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

Global Pregnancy Test Meter Industry 2017 Market Report; Launched via MarketResearchReports.com

In this report, we analyze the Pregnancy Test Meter industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2012 to 2017. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2012 to 2017. We also make a prediction of its production and consumption in coming 2017-2022.

At the same time, we classify different Pregnancy Test Meter based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What is more, the Pregnancy Test Meter industry development trends and marketing channels are analyzed.

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Browse this report: Global Pregnancy Test Meter Industry Market Research 2017

The report can answer the following questions:

1. What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Pregnancy Test Meter?

2. Who are the global key manufacturers of Pregnancy Test Meter industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?

3. What are the types and applications of Pregnancy Test Meter? What is the market share of each type and application?

4. What are the upstream raw materials and manufacturing equipment of Pregnancy Test Meter? What is the manufacturing process of Pregnancy Test Meter?

5. Economic impact on Pregnancy Test Meter industry and development trend of Pregnancy Test Meter industry.

6. What will the Pregnancy Test Meter market size and the growth rate be in 2022?

7. What are the key factors driving the global Pregnancy Test Meter industry?

8. What are the key market trends impacting the growth of the Pregnancy Test Meter market?

9. What are the Pregnancy Test Meter market challenges to market growth?

10. What are the Pregnancy Test Meter market opportunities and threats faced by the vendors in the global Pregnancy Test Meter market?

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Pregnancy Test Meter market.

2. To provide insights about factors affecting the market growth. To analyze the Pregnancy Test Meter market based on various factors- price analysis, supply chain analysis, porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Pregnancy Test Meter market.

Spanning over 161 pages “Global Pregnancy Test Meter Industry Market Research 2017” report covers Industry Overview of Pregnancy Test Meter, Industry Chain Analysis of Pregnancy Test Meter, Manufacturing Technology of Pregnancy Test Meter, Major Manufacturers Analysis of Pregnancy Test Meter, Global Production, Revenue and Price Analysis of Pregnancy Test Meter by Regions, Manufacturers, Types and Applications, Global and Major Regions Capacity, Production, Revenue and Growth Rate of Pregnancy Test Meter 2012-2017, Consumption Volume, Consumption Value, Import, Export and Sale Price Analysis of Pregnancy Test Meter by Regions, Gross and Gross Margin Analysis of Pregnancy Test Meter, Marketing Trader or Distributor Analysis of Pregnancy Test Meter, Global and Chinese Economic Impact on Pregnancy Test Meter Industry, Development Trend Analysis of Pregnancy Test Meter, Contact information of Pregnancy Test Meter, New Project Investment Feasibility Analysis of Pregnancy Test Meter, Conclusion of the Global Pregnancy Test Meter Industry 2017 Market Research Report.

Please visit this link for more details: http://mrr.cm/UpD

For related reports please visit: Pregnancy Test Meter Market Research Reports

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare